Under construction – not a live service
Sign in
Enrolling by invitationNo phase

Home video therapy combined with hospital therapy after stroke or brain injury

Compares mixed home and hospital therapy with hospital-only therapy after stroke or brain injury.

Plain-language title generated from the registry record
Registry title: Comparison of Blended Care Outpatient Neurorehabilitation With Traditional Outpatient Neurorehabilitation

Key facts

Where
Lucerne, SwitzerlandSee the site

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 80 years old?

Source: NCT07458308, who can take part

Where in Switzerland

  • Luzerner KantonsspitalLucerne, SwitzerlandNo longer taking part

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Luzerner Kantonsspital
Trial code
NCT07458308
Record updated
13 April 2026
Original description
What is this study about? Outpatient neurorehabilitation (therapy after leaving the hospital) is an important follow-up treatment for people who have had a stroke, brain bleeding, or serious head injury. It helps improve problems with movement, speech, memory, or daily activities.Read full original descriptionShow less

Comparison of Blended Care Outpatient Neurorehabilitation With Traditional Outpatient Neurorehabilitation, a Crossover Pilot Study

What is this study about? Outpatient neurorehabilitation (therapy after leaving the hospital) is an important follow-up treatment for people who have had a stroke, brain bleeding, or serious head injury. It helps improve problems with movement, speech, memory, or daily activities.

At the same time, there are not enough healthcare professionals, and healthcare costs are rising. Because of this, we need new and more efficient ways to provide therapy.

One possible solution is telerehabilitation. This means patients do part of their therapy at home using video calls and apps. Early studies show that this can work well. However, in Switzerland it is still rarely used. One reason is that digital therapies are often not paid for, and there is still limited scientific proof of how effective they are.

In this study, the investigators want to find out how well a combination of traditional in-person therapy and digital therapy at home works. The goal is to make treatment more modern, effective, and affordable - benefiting patients, therapists, and the healthcare system.

How is the study organized?

Participants in the study are randomly divided into two groups.

Group 1:

First, participants have three weeks of combined therapy:

1. therapy day per week at the hospital. 2. therapy days per week at home via Microsoft Teams video calls. On home days, participants also complete exercises using apps provided by their therapists.

After that, participants have three weeks of therapy fully at the hospital (3 days per week).

Group 2:

First, participants have three weeks of therapy at the hospital (3 days per week).

After that, participants have three weeks of combined therapy (hospital + home video therapy).

Both groups receive the same types of therapy, just in a different order. This is called a crossover design.

Because this is one of the first studies of its kind, the investigators are starting with a small number of participants. This is called a pilot study.

Inclusion: Diagnosis of ischemic or haemorragic stroke or brain trauma; People for whom at least 6 weeks of outpatient rehabilitation is foreseen to be indicated; Ability for safe independent mobilisation (screening with MiniBesTest, Chedoke); Access to and ability to operate MS Teams and Apps on computer and other digital devices (Smartphone, Tablet) (Screening with AST, LAST and NHPT); Able to provide informed consent in German; Age: 18 - 80 years.

Exclusion: Severe cardiopulmonary disease; Other neurological disease than mentioned in the inclusion criteria; Inability to provide informed consent.

ClinicalTrials.gov NCT07458308